These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11751750)

  • 21. Spatial coordination of CD8 and TCR molecules controls antigen recognition by CD8+ T-cells.
    Pecht I; Gakamsky DM
    FEBS Lett; 2005 Jun; 579(15):3336-41. PubMed ID: 15913613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD8 kinetically promotes ligand binding to the T-cell antigen receptor.
    Gakamsky DM; Luescher IF; Pramanik A; Kopito RB; Lemonnier F; Vogel H; Rigler R; Pecht I
    Biophys J; 2005 Sep; 89(3):2121-33. PubMed ID: 15980174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-capping studies reveal CD8/TCR interactions after capping CD8 beta polypeptides and intracellular associations of CD8 with p56(lck).
    Kwan Lim GE; McNeill L; Whitley K; Becker DL; Zamoyska R
    Eur J Immunol; 1998 Feb; 28(2):745-54. PubMed ID: 9521084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of the T cell receptor, CD8, and LFA-1 in different stages of the cytolytic reaction mediated by alloreactive T lymphocyte clones.
    Blanchard D; van Els C; Borst J; Carrel S; Boylston A; de Vries JE; Spits H
    J Immunol; 1987 Apr; 138(8):2417-21. PubMed ID: 3104466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD4-Ia interactions can occur in the absence of T-cell receptor/antigen-Ia recognition.
    Andris F; Leo O; Van Mechelen M; Urbain J; Slaoui M
    Immunology; 1989 Sep; 68(1):1-6. PubMed ID: 2530152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glu227-->Lys substitution in the acidic loop of major histocompatibility complex class I alpha 3 domain distinguishes low avidity CD8 coreceptor and avidity-enhanced CD8 accessory functions.
    Shen L; Potter TA; Kane KP
    J Exp Med; 1996 Nov; 184(5):1671-83. PubMed ID: 8920857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Coreceptor function of CD4 in response to MHC class I molecule].
    Zvezdova ES; Grinenko TS; Pobezinskaia EL; Pobezinskiĭ LA; Kazanskiĭ DB
    Mol Biol (Mosk); 2008; 42(4):662-72. PubMed ID: 18856067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of bispecific heteroconjugated antibodies (anti-T cell antigen receptor x anti-MHC class II) to study activation of T cells with a full length or truncated antigen receptor zeta-chain.
    Wu S; Yang Y; Sadegh-Nasseri S; Ashwell JD
    J Immunol; 1993 Mar; 150(6):2211-21. PubMed ID: 8450208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The roles of CD4 and CD8 in T cell activation.
    Miceli MC; Parnes JR
    Semin Immunol; 1991 May; 3(3):133-41. PubMed ID: 1909592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TCR internalization induced by peptide/MHC ligands requires the transmembrane domains of alphabeta chains of TCR, but not the expression of CD8 and Thy-1 molecules.
    Lee MH; Min D; Sonn CH; Lee KN; Kim KE; Paik SG; Kim YS
    Mol Cells; 1999 Dec; 9(6):617-24. PubMed ID: 10672928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is CD8 dependence a true reflection of TCR affinity for antigen?
    Kwan-Lim GE; Ong T; Aosai F; Stauss H; Zamoyska R
    Int Immunol; 1993 Oct; 5(10):1219-28. PubMed ID: 8268129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric beta2 microglobulin/CD3zeta polypeptides expressed in T cells convert MHC class I peptide ligands into T cell activation receptors: a potential tool for specific targeting of pathogenic CD8(+) T cells.
    Margalit A; Fishman S; Berko D; Engberg J; Gross G
    Int Immunol; 2003 Nov; 15(11):1379-87. PubMed ID: 14565936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble peptide-MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules.
    Ge Q; Stone JD; Thompson MT; Cochran JR; Rushe M; Eisen HN; Chen J; Stern LJ
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13729-34. PubMed ID: 12374859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Class II major histocompatibility complex-peptide tetramer staining in relation to functional avidity and T cell receptor diversity in the mouse CD4(+) T cell response to a rheumatoid arthritis-associated antigen.
    Falta MT; Fontenot AP; Rosloniec EF; Crawford F; Roark CL; Bill J; Marrack P; Kappler J; Kotzin BL
    Arthritis Rheum; 2005 Jun; 52(6):1885-96. PubMed ID: 15934080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-MHC-restricted target-cell lysis by a CD4-CD8- TCR alpha beta T-cell line, as well as by TCR gamma delta T-cell lines, results from lymphokine-activated killing.
    Maziarz RT; Groh V; Prendergast M; Fabbi M; Strominger JL; Burakoff SJ
    Int J Cancer; 1991 Apr; 48(1):142-7. PubMed ID: 1902200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engagement of a T cell receptor by major histocompatibility complex irrespective of peptide.
    Vessey SJ; Barouch DH; McAdam SN; Tussey LG; Davenport MA; O'Callaghan CA; Bell JI; McMichael AJ; Jakobsen BK
    Eur J Immunol; 1997 Apr; 27(4):879-85. PubMed ID: 9130639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thymic Origins of T Cell Receptor Alloreactivity.
    Brzostek J; Gascoigne NRJ
    Transplantation; 2017 Jul; 101(7):1535-1541. PubMed ID: 28114168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Participation of L3T4 in T cell activation in the absence of class II major histocompatibility complex antigens. Inhibition by anti-L3T4 antibodies is a function both of epitope density and mode of presentation of anti-receptor antibody.
    Owens T; Fazekas de St Groth B
    J Immunol; 1987 Apr; 138(8):2402-9. PubMed ID: 2435798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Avidity characterization of genetically engineered T-cells with novel and established approaches.
    Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
    BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.